Literature DB >> 36163500

Computational identification of a systemic antibiotic for gram-negative bacteria.

Ryan D Miller1, Akira Iinishi1, Seyed Majed Modaresi2, Byung-Kuk Yoo3, Thomas D Curtis1, Patrick J Lariviere1, Libang Liang1, Sangkeun Son1, Samantha Nicolau1, Rachel Bargabos1, Madeleine Morrissette1, Michael F Gates1, Norman Pitt1, Roman P Jakob2, Parthasarathi Rath2, Timm Maier2, Andrey G Malyutin4, Jens T Kaiser4, Samantha Niles1, Blake Karavas1, Meghan Ghiglieri1, Sarah E J Bowman5, Douglas C Rees3,6, Sebastian Hiller7, Kim Lewis8.   

Abstract

Discovery of antibiotics acting against Gram-negative species is uniquely challenging due to their restrictive penetration barrier. BamA, which inserts proteins into the outer membrane, is an attractive target due to its surface location. Darobactins produced by Photorhabdus, a nematode gut microbiome symbiont, target BamA. We reasoned that a computational search for genes only distantly related to the darobactin operon may lead to novel compounds. Following this clue, we identified dynobactin A, a novel peptide antibiotic from Photorhabdus australis containing two unlinked rings. Dynobactin is structurally unrelated to darobactins, but also targets BamA. Based on a BamA-dynobactin co-crystal structure and a BAM-complex-dynobactin cryo-EM structure, we show that dynobactin binds to the BamA lateral gate, uniquely protruding into its β-barrel lumen. Dynobactin showed efficacy in a mouse systemic Escherichia coli infection. This study demonstrates the utility of computational approaches to antibiotic discovery and suggests that dynobactin is a promising lead for drug development.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36163500     DOI: 10.1038/s41564-022-01227-4

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   30.964


  71 in total

Review 1.  Antibacterial drug discovery in the resistance era.

Authors:  Eric D Brown; Gerard D Wright
Journal:  Nature       Date:  2016-01-21       Impact factor: 49.962

2.  Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2.

Authors:  Ekaterina Gavrish; Clarissa S Sit; Shugeng Cao; Olga Kandror; Amy Spoering; Aaron Peoples; Losee Ling; Ashley Fetterman; Dallas Hughes; Anthony Bissell; Heather Torrey; Tatos Akopian; Andreas Mueller; Slava Epstein; Alfred Goldberg; Jon Clardy; Kim Lewis
Journal:  Chem Biol       Date:  2014-03-27

3.  A new antibiotic kills pathogens without detectable resistance.

Authors:  Losee L Ling; Tanja Schneider; Aaron J Peoples; Amy L Spoering; Ina Engels; Brian P Conlon; Anna Mueller; Till F Schäberle; Dallas E Hughes; Slava Epstein; Michael Jones; Linos Lazarides; Victoria A Steadman; Douglas R Cohen; Cintia R Felix; K Ashley Fetterman; William P Millett; Anthony G Nitti; Ashley M Zullo; Chao Chen; Kim Lewis
Journal:  Nature       Date:  2015-01-07       Impact factor: 49.962

Review 4.  The Science of Antibiotic Discovery.

Authors:  Kim Lewis
Journal:  Cell       Date:  2020-03-19       Impact factor: 41.582

5.  Predictive compound accumulation rules yield a broad-spectrum antibiotic.

Authors:  Michelle F Richter; Bryon S Drown; Andrew P Riley; Alfredo Garcia; Tomohiro Shirai; Riley L Svec; Paul J Hergenrother
Journal:  Nature       Date:  2017-05-10       Impact factor: 49.962

6.  Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens.

Authors:  Erica N Parker; Bryon S Drown; Emily J Geddes; Hyang Yeon Lee; Nahed Ismail; Gee W Lau; Paul J Hergenrother
Journal:  Nat Microbiol       Date:  2019-11-18       Impact factor: 17.745

Review 7.  Trans-envelope multidrug efflux pumps of Gram-negative bacteria and their synergism with the outer membrane barrier.

Authors:  Helen I Zgurskaya; Valentin V Rybenkov; Ganesh Krishnamoorthy; Inga V Leus
Journal:  Res Microbiol       Date:  2018-02-16       Impact factor: 3.992

8.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Authors:  Evelina Tacconelli; Elena Carrara; Alessia Savoldi; Stephan Harbarth; Marc Mendelson; Dominique L Monnet; Céline Pulcini; Gunnar Kahlmeter; Jan Kluytmans; Yehuda Carmeli; Marc Ouellette; Kevin Outterson; Jean Patel; Marco Cavaleri; Edward M Cox; Chris R Houchens; M Lindsay Grayson; Paul Hansen; Nalini Singh; Ursula Theuretzbacher; Nicola Magrini
Journal:  Lancet Infect Dis       Date:  2017-12-21       Impact factor: 71.421

9.  A Silent Operon of Photorhabdus luminescens Encodes a Prodrug Mimic of GTP.

Authors:  Negar Shahsavari; Boyuan Wang; Yu Imai; Miho Mori; Sangkeun Son; Libang Liang; Nils Böhringer; Sylvie Manuse; Michael F Gates; Madeleine Morrissette; Rachel Corsetti; Josh L Espinoza; Chris L Dupont; Michael T Laub; Kim Lewis
Journal:  mBio       Date:  2022-05-16       Impact factor: 7.786

10.  Novel Antimicrobials from Uncultured Bacteria Acting against Mycobacterium tuberculosis.

Authors:  Jeffrey Quigley; Aaron Peoples; Asel Sarybaeva; Dallas Hughes; Meghan Ghiglieri; Catherine Achorn; Alysha Desrosiers; Cintia Felix; Libang Liang; Stephanie Malveira; William Millett; Anthony Nitti; Baldwin Tran; Ashley Zullo; Clemens Anklin; Amy Spoering; Losee Lucy Ling; Kim Lewis
Journal:  mBio       Date:  2020-08-04       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.